NASH Genotype study
Case-control Study Evaluating Biomarkers and Genetic Factors Associated with the Development of Steatosis, Steatohepatitis and Fibrosis in Patients with Steatotic Liver Disease (SLD).
Steatotic Liver Diseases all involve having excess fat in the liver. This is thought to occur in around 30-50% of the population but often gives no symptoms. It often occurs in people with metabolic disorders such as diabetes, high cholesterol, high blood pressure and excess body weight. In some people, inflammation of the liver (steatohepatitis) can also develop. Some patients also go on to develop serious liver conditions such as scarring, which can lead to cirrhosis or liver failure.
Our study is designed to discover the steps that lead to liver damage and disease progression in steatotic liver diseases (metabolic dysfunction-associated steatotic liver diseases (MASLD and MetALD; previously known as non-alcoholic liver disease or fatty liver disease), and alcohol-related liver disease).
What is our goal?
Our goal is to develop new non-invasive tests to specifically diagnose steatotic liver diseases, as an alternative to liver biopsy.
We aim to include 800 patients with steatotic liver disease and 300 controls (without any liver disease) recruited at centres in the UK.
We will evaluate how genetic variations between people affects their susceptibility to steatotic liver diseases and evaluate potential non-invasive diagnostic tests.
We will not be testing any drugs, treatments or procedures.
Information about taking part in our research study:
We are curently recruiting participants for this study at the Queen's Medical Centre- Nottingham, Aberdeen Royal Infirmary-Scotland and Glasgow Royal Infirmary- Scotland.
If you are interested in this study please contact our research centre 0115 9707966 (ext 80605) or email nddcbru@nottingham.ac.uk
Please view the Patient Information Sheet for more information